Xiao Zhang1, Yukuan Feng2, Xi Liu3, Jianhui Ma1, Yafei Li1, Tianzhen Wang4, Xiaobo Li5. 1. Department of Pathology, Harbin Medical University, Harbin, 150086, China. 2. Key Laboratory of Heilongjiang Province for Cancer Prevention and Control, Mudanjiang Medical University, Mudanjiang, 157011, China. 3. Center of Cardiovascular Disease, Inner Mongolia People's Hospital, Hohhot, 010017, Inner Mongolia, China. 4. Department of Pathology, Harbin Medical University, Harbin, 150086, China. wtzpath@163.com. 5. Department of Pathology, Harbin Medical University, Harbin, 150086, China. lixiaobo@ems.hrbmu.edu.cn.
Abstract
PURPOSE: Aspirin, one of the most commonly used nonsteroidal anti-inflammatory drugs (NAIDS), not only shows cancer chemoprevention effects but also improves cancer therapeutic effects when combined with other therapies. Studies that focus on aspirin regulation of the hallmarks of cancer and the associated molecular mechanisms facilitate a more thorough understanding of aspirin in mediating chemoprevention and may supply additional information for the development of novel cancer therapeutic agents. METHODS: The relevant literatures from PubMed have been reviewed in this article. RESULTS: Current studies have revealed that aspirin regulates almost all the hallmarks of cancer. Within tumor tissue, aspirin suppresses the bioactivities of cancer cells themselves and deteriorates the tumor microenvironment that supports cancer progression. In addition to tumor tissues, blocking of platelet activation also contributes to the ability of aspirin to inhibit cancer progression. In terms of the molecular mechanism, aspirin targets oncogenes and cancer-related signaling pathways and activates certain tumor suppressors. CONCLUSION: Beyond a chemopreventive agent, aspirin is a master regulator of the hallmarks of cancer.
PURPOSE:Aspirin, one of the most commonly used nonsteroidal anti-inflammatory drugs (NAIDS), not only shows cancer chemoprevention effects but also improves cancer therapeutic effects when combined with other therapies. Studies that focus on aspirin regulation of the hallmarks of cancer and the associated molecular mechanisms facilitate a more thorough understanding of aspirin in mediating chemoprevention and may supply additional information for the development of novel cancer therapeutic agents. METHODS: The relevant literatures from PubMed have been reviewed in this article. RESULTS: Current studies have revealed that aspirin regulates almost all the hallmarks of cancer. Within tumor tissue, aspirin suppresses the bioactivities of cancer cells themselves and deteriorates the tumor microenvironment that supports cancer progression. In addition to tumor tissues, blocking of platelet activation also contributes to the ability of aspirin to inhibit cancer progression. In terms of the molecular mechanism, aspirin targets oncogenes and cancer-related signaling pathways and activates certain tumor suppressors. CONCLUSION: Beyond a chemopreventive agent, aspirin is a master regulator of the hallmarks of cancer.
Entities:
Keywords:
Aspirin; Cancer; Cancer therapy; Hallmark of cancers
Authors: Elizabeth L Barry; Veronika Fedirko; Karan Uppal; Chunyu Ma; Ken Liu; Leila A Mott; Janet L Peacock; Michael N Passarelli; John A Baron; Dean P Jones Journal: Cancer Prev Res (Phila) Date: 2020-07-12
Authors: Manpreet Sambi; Vanessa Samuel; Bessi Qorri; Sabah Haq; Sergey V Burov; Elena Markvicheva; William Harless; Myron R Szewczuk Journal: Drug Des Devel Ther Date: 2020-05-25 Impact factor: 4.162
Authors: Raghav Chandra; John D Karalis; Charles Liu; Gilbert Z Murimwa; Josiah Voth Park; Christopher A Heid; Scott I Reznik; Emina Huang; John D Minna; Rolf A Brekken Journal: Cancers (Basel) Date: 2021-12-09 Impact factor: 6.639